Compare Hilton Hotels Corporation Common Stock (HLT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.14B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Hilton Hotels Corporation Common Stock and Regeneron Pharmaceuticals Inc are close in size by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HLT | REGN | |
|---|---|---|
Market Cap | $72.14B | $76.40B |
Volume | 862,817 | 626,381 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $852.03 |
52-Week Low | $256.96 | $557.73 |
Typical Hold Time | 138 Days | 107 Days |
Enterprise Value | $85.15B | $71.12B |
Dividend Yield | 0.19% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.29, up 0.21% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $12.04B in 2025, with net income of $1.46B and consistent quarterly EPS beats. Recent news highlights upcoming Q3 2026 earnings and positive travel trends for 2027.
Outlook remains positive with a consensus price target of $348.11, though high debt levels and valuation multiples pose risks. Earnings growth and global expansion in Asia present opportunities, but investors should monitor interest expense and competitive pressures in the hospitality sector.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
